Journal of Neuro-Oncology

, Volume 110, Issue 2, pp 279–285

Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

  • Matthias Holdhoff
  • Xiaobu Ye
  • Jaishri O. Blakeley
  • Lindsay Blair
  • Peter C. Burger
  • Stuart A. Grossman
  • Luis A. DiazJr.
Clinical Study

Abstract

This study was conducted to assess the current pattern of use and the impact of available molecular predictive and prognostic biomarkers on clinical care in patients with glioblastoma (GBM). An online questionnaire consisting of 15 questions about the frequency of use and clinical utility of tissue-based molecular tests was distributed to 1,053 members of the Neuro-Oncology Community in the United States. A total of 320 responses (30.4 %) were collected. 73 respondents who did not see GBM patients were excluded from analysis. MGMT promoter methylation testing (MGMT-meth) was the most commonly requested (37.2; 95 % CI, 31–44), followed by EGFR amplification (22.7; 95 % CI, 18–28), co-deletion of 1p/19q (22.3 %), EGFR expression (21.5 %), P53 mutation (19.8 %), PTEN mutation or deletion (17.4 %), EGFRvIII mutation (12.1 %), IDH1/2 mutation (12.1 %), PDGFR (4.5 %), and PIK3CA (0.8 %). The perceived utility of these studies was variable between participants. A small percentage of respondents felt that any of the studies were “always” or “almost always” helpful in clinical decision making (MGMT-meth 10.9 %; range, 0–13.8 %), but more frequently “never” or “almost never” helpful (MGMT-meth 25.9 %; range, 25–54.7 %). 26.7 % reported not to routinely order any of these studies. Although molecular markers are frequently ordered for patients with GBM, only a minority of clinicians ordering these tests report that the results influence clinical decision-making. Molecular markers that are likely to affect patient care should be ordered with the goal to maximize benefit for patients and to avoid non-actionable results and additional costs.

Keywords

Molecular biomarker Glioblastoma MGMT promoter methylation Prognostic biomarker Personalized medicine 

Supplementary material

11060_2012_968_MOESM1_ESM.docx (384 kb)
Supplementary material 1 (DOCX 24 kb)

References

  1. 1.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.1016/S1470-2045(09)70025-7 PubMedCrossRefGoogle Scholar
  2. 2.
    Holdhoff M, Grossman SA (2011) Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 16:351–358PubMedCrossRefGoogle Scholar
  3. 3.
    Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. doi:10.1126/science.1164382 PubMedCrossRefGoogle Scholar
  4. 4.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. doi:10.1056/NEJMoa0808710 PubMedCrossRefGoogle Scholar
  5. 5.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331 PubMedCrossRefGoogle Scholar
  6. 6.
    Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518. doi:10.1002/cncr.24406 PubMedCrossRefGoogle Scholar
  7. 7.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
  8. 8.
    Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199. doi:10.1200/JCO.2007.11.5964 PubMedCrossRefGoogle Scholar
  9. 9.
    van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276–1284. doi:10.1002/cncr.11187 PubMedCrossRefGoogle Scholar
  10. 10.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024. doi:10.1056/NEJMoa051918 PubMedCrossRefGoogle Scholar
  11. 11.
    Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150PubMedGoogle Scholar
  12. 12.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181–185. doi:10.1016/j.bcmd.2004.11.006 PubMedCrossRefGoogle Scholar
  13. 13.
    Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American Brain Tumor Consortium Study 99–08. Clin Cancer Res 12:4899–4907. doi:10.1158/1078-0432.CCR-06-0773 Google Scholar
  14. 14.
    Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359–9368. doi:10.1200/JCO.2005.03.2185 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Matthias Holdhoff
    • 1
    • 2
    • 3
  • Xiaobu Ye
    • 1
  • Jaishri O. Blakeley
    • 1
  • Lindsay Blair
    • 1
  • Peter C. Burger
    • 1
  • Stuart A. Grossman
    • 1
  • Luis A. DiazJr.
    • 2
    • 3
  1. 1.Brain Cancer Program, Department of OncologySidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA
  2. 2.Ludwig Center for Cancer Genetics and Therapeutics at Johns HopkinsBaltimoreUSA
  3. 3.The Swim Across America Laboratory at Johns HopkinsBaltimoreUSA

Personalised recommendations